Michigan Biomedical Venture Fund

What Michigan Biomedical Venture Fund does

Michigan Biomedical Venture Fund is a university-affiliated seed-stage venture capital program operated as a unit of the University of Michigan Medical School's Office of Research, sitting within the Fast Forward Medical Innovation (FFMI) ecosystem. The fund makes equity investments in early-stage biomedical startup companies that have licensed University of Michigan intellectual property, focused on four domains: therapeutics, medical devices, diagnostics, and health information technology. Its investee base consists of U-M faculty, researchers, and student entrepreneurs seeking capital and commercialization pathways for university-developed IP. The fund is differentiated from independent seed-stage VCs by its structural access to a captive pipeline of U-M biomedical IP and to the FFMI commercialization support stack, which includes mentorship, education programs, business development, and industry partnerships.

The fund's core offering is a combination of equity capital plus ecosystem support rather than a standalone financial product. Portfolio companies gain access to FFMI's business development team, the Frankel CVC and Rogel Cancer Center innovation programs, the MTRAC statewide life sciences hub, the Center for Entrepreneurship, Zell Lurie Institute, MICHR, and Pfizer co-developed educational programming such as the Oncology Drug Discovery & Development Workshop. Distribution is direct, via internal deal sourcing from the U-M research community rather than through external intermediaries, and marketing is conducted through FFMI's monthly newsletter, webinar series, and events such as Researchpalooza.

Economically, the fund does not report revenue, AUM, or management fees; its value accrues through equity stakes in portfolio companies. According to disclosed scale metrics, 21 portfolio startups have generated $350M+ in follow-on investment, and the broader U-M ecosystem has attracted $147M in Industry Research Awards. The fund has 1-10 employees, is headquartered in Ann Arbor, Michigan, and is led operationally by Program Manager Hirak Parikh.

Name

Michigan Biomedical Venture Fund

Legal name

Michigan Biomedical Venture Fund

Website

https://innovation.medicine.umich.edu

Company type

Private

Founded year

1869

Operating status

Operating

Headcount range

1–10 employees

Short description

Michigan Biomedical Venture Fund is a seed-stage venture program within the University of Michigan Medical School that invests equity in early-stage biomedical startups commercializing U-M licensed intellectual property across therapeutics, medical devices, diagnostics, and health IT.

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Other Financial Vehicles (52599)

SIC

Investment Advice (6282)

akta.pro primary industry

Early-Stage Venture Capital (Pre-Seed/Seed) (FSANAAAA)

akta.pro secondary industries

Early-Stage Venture Capital (Series A/B) (FSANAAAB), Research & Science Grantmaking Foundations (BPAGAKAI), Healthcare Access & Life Sciences Impact Funds (FSANAJAI)

Keywords

• Venture capital funding
• Biomedical startups
• Seed investment
• Medical innovation
• University spinouts

Headquarters

HQ city

Ann Arbor

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations

Revenue model

1. Investment Returns: The fund generates returns through equity investments in biomedical startup companies. Portfolio companies operate in therapeutics, medical devices, diagnostics, and health IT sectors, with IP licensed from the University of Michigan.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

The Michigan Biomedical Venture Fund provides seed-stage equity funding to early-stage University of Michigan biomedical startups commercializing U-M licensed intellectual property. Operated within the Fast Forward Medical Innovation (FFMI) ecosystem at the U-M Medical School, the fund targets nascent spinouts in therapeutics, medical devices, diagnostics, and health IT.

Product overview

Michigan Biomedical Venture Fund is a single investment program focused on early-stage biomedical startups. It provides capital investments to companies commercializing University of Michigan-licensed intellectual property across four key domains: therapeutics, medical devices, diagnostics, and health information technology. The fund is part of the Fast Forward Medical Innovation ecosystem at the University of Michigan Medical School and represents the primary investment vehicle within that commercialization support structure.

Differentiator

Problem solved

Functional benefit

Products and services

• Michigan Biomedical Venture Fund

Quantifiable outcome

• $350M+ in follow-on investment generated by 21 portfolio companies

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eight partnerships are on record, tiered key and core.

• PfizerkeyStrategic or Co-development PartnerPfizer partners with Fast Forward Medical Innovation to offer the Oncology Drug Discovery & Development (3D) Workshop, an educational program providing participants with interactive, team-based learning experience in drug discovery and development.
• Frankel Cardiovascular CentercoreStrategic or Co-development PartnerFrankel CVC Innovation Program provides specialized commercialization support and funding opportunities for cardiovascular innovations within the FFMI ecosystem.
• Rogel Cancer CentercoreStrategic or Co-development PartnerRogel Cancer Center Innovation Program offers targeted support for cancer-related innovations through FFMI's commercialization education and mentorship programs.
• MTRAC Innovation Hub for Life SciencescoreStrategic or Co-development PartnerStatewide Michigan Translational Research and Commercialization (MTRAC) program provides funding and commercialization support for life sciences innovations.
• Center for EntrepreneurshipcoreStrategic or Co-development PartnerUniversity-wide entrepreneurship center provides cross-disciplinary support and resources for biomedical innovators.
• Zell Lurie InstitutekeyStrategic or Co-development PartnerPart of the FFMI ecosystem, providing entrepreneurship resources and support for University of Michigan researchers and students.
• MICHR (Michigan Institute for Clinical & Health Research)coreStrategic or Co-development PartnerClinical and translational research institute that supports the biomedical innovation ecosystem and research commercialization efforts.
• Industry PartnerskeyStrategic or Co-development PartnerFFMI's Business Development team builds relationships between U-M biomedical researchers and corporate partners, facilitating collaborations and industry partnerships.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Atlas Venture: Long-running early-stage biotech and biomedical venture firm; relevant comparable as a seed/Series A investor in therapeutics and biomedical platforms, though operating as a traditional private fund rather than a university program.
• Foresite Capital: Healthcare and biomedical-focused venture firm investing across therapeutics, diagnostics, and devices; a relevant peer for biomedical early-stage investing, though with broader institutional LP backing.
• ARCH Venture Partners: Established deep-tech and biomedical venture firm with deep university-spinout roots; competes for the same university-licensed biomedical opportunities at much larger fund sizes.
• The Column Group: Biomedical-focused venture firm investing in early-stage therapeutics companies, including many university-spinout opportunities; relevant comparable for the fund's therapeutics focus.

Regional players

• BioEnterprise: Biomedical and health IT commercialization organization supporting regional startup formation — thematically comparable as a regional biomedical commercialization hub, though operating in a different geography.
• MBC BioLabs: Bay Area biotech incubator supporting early-stage biomedical startup formation with lab infrastructure — adjacent comparable for biomedical startup formation support, though geographically distinct.

Direct peers

• Wisconsin Alumni Research Foundation (WARF): University-affiliated technology transfer and investment organization for the University of Wisconsin that licenses IP and seeds biomedical startups — directly comparable as a university-based biomedical commercialization and investment vehicle.
• Osage University Partners: Venture fund that invests exclusively in startups commercializing technology from its partner universities — a structurally analogous model to Michigan Biomedical Venture Fund's U-M-only IP investment thesis.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Michigan Biomedical Venture Fund